Alnylam Obtains Continued Funding From NIAID for Anti-Viral Program
Alnylam Pharmaceuticals has announced that the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, has committed to $7.5 million of continued funding related to the 2006 contract for the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever virus, including Ebola virus.
In September 2006, Alnylam was awarded a federal contract providing the company with up to $23 million in funding over a four-year period to develop small interfering RNAs (siRNAs), the molecules that mediate RNAi, as anti-viral drugs targeting Ebola virus.
To date, the government has committed to paying Alnylam up to $14.2 million for the first two years of the contract. As a result of the continued progress of this program, the government has committed to fund an additional $7.5 million over year three of the contract.
Antonin de Fougerolles, senior director of research at Alnylam, said: “We are encouraged by the data we have seen with the Ebola program. These data have demonstrated potent and specific in vivo efficacy mediated by an RNAi mechanism. This funding from the National Institute of Allergy and Infectious Diseases (NIAID) allows us to continue to develop our technology as we advance our pipeline programs.”